Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)

April 24, 2024 07:12 AM EDT

Roche doubles down on high-impact projects after slashing 20% of its pipeline

Ayisha Sharma

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation